ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Santen has signed an agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein for retinal ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial ...

Turkey: A retrospective single-center study published in BMC Ophthalmology has highlighted the potential role of intravitreal ...

To study visual and anatomical outcomes of sequenced combined therapy using intravitreal bevacizumab followed by photodynamic therapy (PDT) in eyes with retinal angiomatous proliferation (RAP ...

Intravitreal bevacizumab for nonarteritic anterior ischemic optic neuropathy: a pilot study. In: Proceeds from the Meeting of the North American Neuro-Ophthalmological Society. Lake Tahoe, NV, 2009.

KOLOA, Hawaii — Retina specialists have a lot of options when it comes to intravitreal injection procedures, according to a speaker at Retina 2025. Michael Singer, MD, said that every part of ...

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy Technology appraisal guidance TA613 Published: ...